加载中
NASDAQHealthcareBiotechnology
最新数据
US$1.73
US$0.00 · 0.00%
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
收盘时
US$1.73
US$0.00 · 0.00%
盘后
US$1.73
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
日内区间
当前US$1.73
52周区间
当前US$1.73
盘中时间采用ET。市场数据可能有所延迟。
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada.
日内区间
当前US$1.73
52周区间
当前US$1.73
营业利润
净利润
| 项目（CAD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 8.37万 CAD | 14.5万 CAD | 11.41万 CAD | 4.3万 CAD |
| 毛利 | — | −8.37万 CAD | −14.5万 CAD | −11.41万 CAD | −4.3万 CAD |
| 研究与开发 | 1390.72万 CAD | 1565.94万 CAD | 800.06万 CAD | 1642.58万 CAD | 688.29万 CAD |
| 销售、一般及管理费用 | 1117.2万 CAD | 917.22万 CAD | 963.26万 CAD | 628.27万 CAD | 598.28万 CAD |
| 营业费用 | 2507.93万 CAD | 2483.15万 CAD | 1763.32万 CAD | 2270.84万 CAD | 1286.57万 CAD |
| 利息收入 | 33.34万 CAD | 81.21万 CAD | 55.01万 CAD | 19.96万 CAD | 2.96万 CAD |
| 利息支出 | — | — | — | 51.01万 CAD | — |
| 折旧和摊销 | 5.58万 CAD | 8.37万 CAD | 14.5万 CAD | 11.41万 CAD | 4.3万 CAD |
| 营业利润 | −2507.93万 CAD | −2491.53万 CAD | −1777.82万 CAD | −2282.25万 CAD | −1290.87万 CAD |
| 净利润 | −4411.73万 CAD | −2398.98万 CAD | −2238.4万 CAD | −2054万 CAD | −1282.34万 CAD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 593.64%报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
